Literature DB >> 6234685

Mixed lymphocyte culture responses. Lack of correlation with cadaveric renal allograft survival and blood transfusions.

J R Jeffery, K Cheung, J Masniuk, D Taylor.   

Abstract

One-way and two-way mixed lymphocyte reactions (MLRs) between 65 cadaveric renal allograft recipients (R) and their specific-donor (D) and pooled third-party (P) cells were measured using a 5-day assay. There was no correlation between the results expressed as stimulation index, absolute counts, or the relative response and graft survival in transfused allograft recipients. Nontransfused recipients whose first graft failed had significantly higher responses to P, but not D, than those with successful grafts. The one-way MLRs to P of 61 cadaveric graft recipients and 52 potential recipients were measured. No correlation was found between the magnitude of the response and the number of transfusions, time since the last transfusion, or peak cytotoxic antibody production. Our results suggest that a standard 5-day MLR has little clinical value in predicting the results of cadaveric transplantation in HLA-A,B-mismatched recipient-donor pairs. We could not demonstrate any overall effect of transfusions on the MLR, suggesting that this may not be the mechanism by which transfusions exert their effect on graft survival.

Entities:  

Mesh:

Year:  1984        PMID: 6234685

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Prediction of graft prolongation by mixed lymphocyte culture following anti-CD4 monoclonal antibody treatment among different donor-recipient combinations.

Authors:  K Hamano; H Ito; B Shirasawa; H Gohra; T Katoh; Y Fujimura; K Esato
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation.

Authors:  Jennifer R Zitzner; Anat R Tambur
Journal:  Cells       Date:  2012-05-10       Impact factor: 6.600

3.  Virtual Global Transplant Laboratory Standard Operating Protocol for Donor Alloantigen-specific Interferon-gamma ELISPOT Assay.

Authors:  Robert Carroll; Alexander Troelnikov; Anita S Chong
Journal:  Transplant Direct       Date:  2016-10-20

4.  CD147 blockade as a potential and novel treatment of graft rejection.

Authors:  Jing Luan; Yu Zhao; Yang Zhang; Jinlin Miao; Jia Li; Zhi-Nan Chen; Ping Zhu
Journal:  Mol Med Rep       Date:  2017-08-09       Impact factor: 2.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.